Skip to main content
. Author manuscript; available in PMC: 2016 Sep 17.
Published in final edited form as: Chem Biol. 2015 Sep 10;22(9):1238–1249. doi: 10.1016/j.chembiol.2015.08.005

Figure 5. Microbial β-Glucuronidase Inhibitors in Mice Treated with CPT-11.

Figure 5

(A) CPT-11 (irinotecan) produced delayed diarrhea in 25%, 60%, and 100% of mice in 8, 9, and 10 days, respectively. Oral delivery of Inhibitor R1, a 1.9-μM inhibitor of E. coli β-glucuronidase, reduces the number of mice that experience diarrhea at days 9 and 10 to 40% and 60%, respectively, but is less effective than Inhibitor 1, a 0.16-μM inhibitor, on which it was based. N = 9 mice per group.

(B) The circulating plasma levels of CPT-11, its active metabolite SN-38, or its inactive glucuronide conjugate SN-38-G are unaffected by the oral delivery of the microbial β-glucuronidase Inhibitor 1 (Inh1).